BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
March 22, 2022 05:00 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...